Abstract:Background Programmed necrosis/necroptosis is an emerging form of cell death that plays important roles in mammalian development and the immune system. The pro-necrotic kinases in the receptor interacting protein (RIP) family are crucial mediators of programmed necrosis. Recent advances in necrosis research have been greatly aided by the identification of chemical inhibitors that block programmed necrosis. Necrostatin-1 (Nec-1) and its derivatives were previously shown to target the pro-necrotic kinase RIP1/RIPK1. The protective effect conferred by Nec-1 and its derivatives in many experimental model systems was often attributed to the inhibition of RIP1 function. Methodology/Principal Findings We compared the effect of Nec-1 and siRNA-mediated silencing of RIP1 in the murine fibrosarcoma cell line L929. Treatment of L929 cells with the pan-caspase inhibitor zVAD-fmk or exogenous TNF induces necrosis. Strikingly, we found that siRNA-mediated silencing of RIP1 inhibited zVAD-fmk induced necrosis, but not TNF-induced necrosis. TNF-induced cell death in RIP1 knocked down L929 cells was inhibited by Nec-1, but not the caspase inhibitor zVAD-fmk. We found that PKA-C§ expression, but not Jnk or Erk activation, was moderately inhibited by Nec-1. Moreover, we found that Nec-1 inhibits proximal T cell receptor signaling independent of RIP1, leading to inhibition of T cell proliferation. Conclusions/Significance Our results reveal that besides RIP1, Nec-1 also targets other factors crucial for necrosis induction in L929 cells. In addition, high doses of Nec-1 inhibit other signal transduction pathways such as that for T cell receptor activation. These results highlight the importance to independently validate results obtained using Nec-1 with other approaches such as siRNA-mediated gene silencing. We propose that some of the previous published results obtained using Nec-1 should be re-evaluated in light of our findings.

Rip1/Rip3-Regulated Necroptosis As A Target For Multifaceted Disease Therapy (Review)

Inhibition of Receptor-Interacting Protein 3 Upregulation and Nuclear Translocation Involved in Necrostatin-1 Protection Against Hippocampal Neuronal Programmed Necrosis Induced by Ischemia/reperfusion Injury.

Necroptosis in Inflammatory Bowel Disease and Other Intestinal Diseases

RIPK3 signaling and its role in regulated cell death and diseases

Molecular Insights into the Mechanism of Necroptosis: The Necrosome as a Potential Therapeutic Target

The Potential Role of Necroptosis in Clinical Diseases (Review)

Necroptosis in health and diseases

Using Drugs to Target Necroptosis: Dual Roles in Disease Therapy.

Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.

Necroptosis inhibitors: mechanisms of action and therapeutic potential

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Recent advances in signal pathway of necroptosis and necroptosis targeted therapies

The role of necroptosis, an alternative form of cell death, in cancer therapy.

Mitochondrial Mechanisms of Necroptosis in Liver Diseases

The resurrection of RIP kinase 1 as an early cell death checkpoint regulator-a potential target for therapy in the necroptosis era

RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation

Necroptosis: an emerging form of programmed cell death.

Receptor Interacting Protein Kinases 1/3: The Potential Therapeutic Target for Cardiovascular Inflammatory Diseases

Necroptosis: a regulated inflammatory mode of cell death

Protein phosphorylation and kinases: Potential therapeutic targets in necroptosis

Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases